The comment came hours after Bharat Biotech announced that its vaccine Covaxin's efficacy against COVID-19 is 77.8%. "It is good that these results have finally been published and this will help to get Covaxin the WHO emergency use listing. People who have been administered Covaxin in India will be able to travel without restrictions," Arora told news agency ANI. The Hyderabad-based Bharat Biotech has released its data from the final analysis of Covaxin efficacy as part of phase 3 clinical trials. An expert panel of the country's central drugs authority had reviewed and accepted the phase-3 trial data of Bharat Biotech's Covid-19 vaccine Covaxin last month.

Source: Mint July 03, 2021 15:00 UTC